53 citations
,
May 2010 in “PubMed” This paper discusses spironolactone as a potential off-label treatment for female pattern hair loss, noting its ability to halt hair loss progression and induce partial regrowth in a significant number of women but reports no new clinical results.
815 citations
,
April 2010 in “The Journal of Clinical Endocrinology & Metabolism” This review examines the relationship between polycystic ovary syndrome and cardiovascular disease risk, but reports no new clinical findings; the panel calls for guidelines to prevent CVD in this population.
989 citations
,
August 2007 in “The Lancet” This article reviews the clinical features, diagnostic criteria, and possible genetic and environmental influences of polycystic ovary syndrome but provides no new research findings.
166 citations
,
March 2007 in “Hypertension” In this study, hyperandrogenemia in young women with polycystic ovary syndrome was linked to higher blood pressure, independent of factors like age, insulin resistance, obesity, or dyslipidemia.
1744 citations
,
August 2006 in “The Journal of Clinical Endocrinology and Metabolism” This review discusses definitions of polycystic ovary syndrome and reports no new clinical results; the authors support using modified 1990 NIH criteria and acknowledge ongoing evolution as research advances.
155 citations
,
March 2006 in “The American Journal of Medicine” This study found that young women with polycystic ovary syndrome have altered endothelial function associated with insulin resistance and lower adiponectin levels.
947 citations
,
February 2004 in “The Journal of Clinical Endocrinology and Metabolism” In this study, polycystic ovary syndrome was the most prevalent cause of androgen excess, and suppressive hormonal therapy improved hirsutism, menstrual dysfunction, and acne in most patients, though side effects were common.
4809 citations
,
January 2004 in “Fertility and Sterility” This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.
418 citations
,
June 2003 in “Endocrine Reviews” This review discusses the relationship between polycystic ovary syndrome and cardiovascular risk, noting a possible adverse impact on risk profiles and subclinical atherosclerosis but no clear increase in premenopausal cardiovascular events; it presents no new clinical results.
60 citations
,
April 2003 in “Human Reproduction” This study found that Czech women with polycystic ovary syndrome in their thirties had a significantly worse cardiovascular risk profile compared to a control group, independent of obesity.
27 citations
,
May 2002 in “The Journal of Clinical Endocrinology & Metabolism” This study found that brothers of women with PCOS exhibit elevated DHEAS levels, indicating a potential familial genetic trait, but did not show increased rates of premature balding.
298 citations
,
July 2000 in “The Journal of Clinical Endocrinology and Metabolism” This study found a 6.5% prevalence of polycystic ovary syndrome among a population of Caucasian women in Spain, based on specific endocrine criteria.
378 citations
,
September 1998 in “The Journal of Clinical Endocrinology and Metabolism” This study found that the prevalence of PCOS in a population of unselected U.S. women was 4.0%, with no significant racial differences between White and Black women.
39 citations
,
November 1978 in “Annals of internal medicine” This brief report discusses spironolactone used as a treatment for hirsutism in a hyperandrogenic woman, offering no new clinical findings and focusing on its antiandrogenic properties.
